Stockreport

Mustang Bio Announces Publication in Nature Medicine of Data from Phase 1 Trial Evaluating MB-101 IL13Ra2-targeted CAR T-Cells in High-Grade Glioma

Mustang Bio, Inc.  (MBIO) 
Last mustang bio, inc. earnings: 11/12 07:30 am Check Earnings Report
US:NASDAQ Investor Relations: mustangbio.com/investor-relations
PDF MB-101 was well-tolerated and 50% of patients achieved stable disease or better with two partial responses and two complete responses lasting 7.5 and 66+ months, respect [Read more]